Gerresheimer partnered with startup MedTech Adamant Health to revolutionize Parkinson’s disease treatment

Partners join forces to improve the lives of millions of Parkinson’s patients worldwide with a transformative technology-based solution

Gerresheimer participated in the opening round of the Finnish company MedTech and the separation of the university

Monitoring and personalized adjustment of drugs in combination are new

DUSSELDORF, Germany and KUOPIO, Finland, June 13, 2022 / PRNewswire / – Gerresheimer AG and Finnish startup MedTech Adamant Health Oy have partnered to develop a life-changing solution for millions of people worldwide suffering from Parkinson’s disease. The technology and measurement platform being developed will address one of the biggest obstacles to treating Parkinson’s symptoms: Determining the optimal time to take medications to suppress symptoms. In the future, Adamant Health’s measurement and analysis technology and Gerresheimer’s digital platform solution will help determine the exact time to administer medications and inform patients as well as medical staff about the patient’s treatment and the development of symptoms. The benefit for patients: Symptoms become much more stable and predictable. This allows them to live their daily lives in a more independent, safe and satisfying way.

“Our common goal is to optimize the treatment of Parkinson’s disease and drastically improve the quality of life of patients,” he said. Dietmar Zimsen, CEO of Gerresheimer AG. “The investment is part of our strategic expansion into personalized drug delivery devices combined with platform-based and digital disease monitoring. It will also complement our offering of high value solutions to customers, as defined in our Formula One strategic process formula, ”he added.

Parkinson’s disease is a progressive disorder of the nervous system and causes recurrent tremors, stiffness and slowness of movement. Although currently incurable, medications can significantly relieve symptoms. The disease affects approximately 10 million patients worldwide.

“We expect the number of people with Parkinson’s to double in the next 30 years,” they said. Paul Carpelan, CEO of Adamant Health Oy. “Our measurement and analysis service with its unique technologies aims to help individualize therapies and therefore significantly improve the quality of life of patients,” he added.

Adamant Health is a start-up company and a branch of the University of Eastern Finland. It aims to revolutionize Parkinson’s therapy based on 15 years of experience in academic research. The company applies scientific insights to the individual analysis of neuromuscular function and movement.

Gerresheimer participates in the opening round of Adamant Health and is a major industry partner in this round.

By partnering, Gerresheimer and Adamant Health are filling a gap in the treatment of Parkinson’s patients. Novelty is a combination of monitoring and personalized correction of drugs. In the field of monitoring neurodegenerative chronic disease, Adamant Health already occupies a unique position: current technologies used to monitor disease progression only collect data on the patient’s physical movement. The sensor used in Adamant Health’s solution links this feature to a technology called surface electromyography (EMG). local measurement of electrical neuromuscular activity.

Parkinson’s disease is caused by the death of certain nerve cells in the brain. This leads to a deficiency of the neurotransmitter dopamine. Among other things, dopamine plays a key role in controlling muscle function – and thus movement. The goal of drug treatment is to normalize the concentration of this neurotransmitter. To achieve this, the drug must be precisely adjusted and adjusted at regular intervals. This is possible thanks to micropumps such as the D-Mine pump from Gerresheimer.

Adamant Health technology is designed to be widely used for the benefit of all people suffering from Parkinson’s disease, drug development, and research. The partnership aims to combine this technology with personalized medical treatment solutions, such as the existing pump manufactured by Gerresheimer and others, which make it accessible to all Parkinson’s patients. This allows real-time data collection and analysis and precise and continuous adjustment of home medication applications. A solution that will significantly improve the lives of millions of people affected.

concerning Gereshheimer

Gerresheimer is a global partner in pharmaceuticals, biotechnology, healthcare and cosmetics with a very wide product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is a provider of innovative solutions from concept to delivery of the final product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and a focus on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on an extensive international network with many innovation and production centers in EuropeAmerica and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual revenues in 2021 of around 1.5 billion euros. With its products and solutions, Gerresheimer plays an important role in human health and well-being.
www.gerresheimer.com

About Adamant

Adamant Health Ltd. is a health technology company based on research innovation focused on developing and providing services for measuring and analyzing Parkinson’s disease and other motor disorders. The new technology is based on over 15 years of research and clinical trials conducted at the University of Eastern Finland. Adamant Health’s mission is to bring research results to people with mobility impairments by enabling clinicians, pharmaceutical companies and researchers to base their work on objective and detailed data on real-world patients, measured as part of their daily lives. patients.
https://www.adamanthealth.com/

Contact the press
Wellie Utzinger
Senior Director of Marketing and Communications
+49 211 6181-250
[email protected]

Contact the investor relations department
Carolyn Nadilo
Corporate Senior Director of Investor Relations
+49 211 6181-220
[email protected]

Contact Adamant Health Oy
Paul Carpelan
Chief Executive Officer Adamant Health Oy
+358 50 486 7516
[email protected]

SOURCE Gerresheimer AG

Leave a Comment

Your email address will not be published.